Ryan Kim, MD
Ophthalmology · Duncanville, TXNPI 1497384341
Payments from drug & device makers
Across 61 payments — averaging $61.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$910
- Sight Sciences, Inc.$347
- Amgen$281
- Johnson & Johnson Surgical Vision, Inc.$262
- Biotissue Holdings Inc.$187
- plus $343 from 8 others
What the payments were for
- Consulting fees$95026%
- Food & beverage$2,77574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $1,394 |
| Alcon | 16 | $910 |
| Sight Sciences, Inc. | 7 | $347 |
| Amgen | 5 | $281 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $262 |
| Biotissue Holdings Inc. | 8 | $187 |
| Tarsus Pharmaceuticals, Inc. | 4 | $120 |
| Glaukos Corporation | 2 | $76 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Harrow Eye, LLC | 2 | $34 |
| Dompe US, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Rxsight Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$950
- Clareon$394
- Clareon PanOptix Pro$274
- OMNI(R) SURGICAL SYSTEM (US)$274
- SION SURGICAL INSTRUMENT$274
- LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE$262
- LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE)$262
- MEIBOMIAN GLAND EVALUATOR$262
- LIPIVIEW OCULAR SURFACE INTERFEROMETER$262
- XEN GLAUCOMA TREATMENT SYSTEM$252
- AcrySof IQ PanOptix UV IOL$136
- AcrySof IQ VIVITY$136
- TEPEZZA$125
How this compares
$3,725 in reported general payments places this provider in the 65th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 93 | $2,924 |
| Loteprednol Etabonate | 13 | $1,668 |
| Brimonidine Tartrate | 54 | $1,585 |
| Latanoprost | 142 | $1,302 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 81 | $831 |
| Ketorolac Tromethamine | 32 | $760 |
| MoxifloxacinMoxifloxacin Hcl | 28 | $696 |
| Dorzolamide Hcl | 18 | $304 |
| Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate | 13 | $145 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Duncanville
- Andy LeeDuncanville$579K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.